Vivos Therapeutics opens new sleep testing center near Detroit

Vivos Therapeutics, Inc. reported that it issued a press release announcing the grand opening of its latest sleep testing and treatment center near Detroit, in Auburn Hills, Michigan.

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. reported that it issued a press release announcing the grand opening of its latest sleep testing and treatment center near Detroit, in Auburn Hills, Michigan. The full text of the press release, dated December 16, 2025, is included as Exhibit 99.1 to the report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vivos Therapeutics (VVOS) disclose in this Form 8-K?

Vivos Therapeutics disclosed that it issued a press release announcing the grand opening of its latest sleep testing and treatment center near Detroit, in Auburn Hills, Michigan, on December 16, 2025.

Where is Vivos Therapeutics' new sleep testing and treatment center located?

The new sleep testing and treatment center is located in Auburn Hills, Michigan, near Detroit.

When was the Vivos Therapeutics (VVOS) press release about the new center issued?

The press release announcing the grand opening of the new sleep testing and treatment center was issued on December 16, 2025.

Which exhibit in the Vivos Therapeutics 8-K contains the full press release?

The full press release is included as Exhibit 99.1 to the report.

Who signed the Vivos Therapeutics (VVOS) Form 8-K and in what capacity?

The report was signed on behalf of Vivos Therapeutics, Inc. by Bradford Amman, who serves as Chief Financial Officer.

What additional exhibit is referenced in the Vivos Therapeutics 8-K filing?

The filing also references Exhibit 104, the cover page interactive data file formatted in Inline XBRL.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/16/2025 - 05:54 PM Learn about SEC filing dates

false 0001716166 0001716166 2025-12-16 2025-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2025

Vivos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39796		81-3224056
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

7921 Southpark Plaza, Suite 210

Littleton, Colorado 80120

(Address of principal executive offices) (Zip Code)

(866) 908-4867

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		VVOS		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Information.

On December 16, 2025, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing the grand opening of its latest sleep testing and treatment center near Detroit in Auburn Hills, Michigan. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated December 16, 2025
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VIVOS THERAPEUTICS, INC.
Dated: December 16, 2025	By:	/s/ Bradford Amman
	Name:	Bradford Amman
	Title:	Chief Financial Officer